



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Opp. PCI, Ankleshwar – 393 002,
Gujarat, India
Tel : +91-7045456789 / 7046456789
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India.
Tel : (91-22) 26701050/1/2/3
Email: contact@samratpharmachem.in

May 30, 2023

To,
Department of Corporate Services,
BSE Limited
25th Floor, P J Towers,
Dalal Street,
Mumbai - 400 001.

Ref: Scrip Code: 530125

Sub: Disclosure of Related Party Transactions for the half year ended March 31, 2023

Dear Sir / Madam,

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR), we enclose herewith disclosure of related party transactions in the format specified under SEBI circular no. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021, for the half year ended March 31, 2023.

The disclosure is also being uploaded on the website of the company i.e. "www.samratpharmachem.com"

Please take the same on your records.

Thanking you,

Yours faithfully,
For Samrat Pharmachem Limited

Nishant Kankaria
Company Secretary & Compliance Officer

Related party transactions																				
											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)			Interest Rate (%)
1	Lalit Damodar Mehta	AABPM9691E	Samrat Pharmachem Limited	AAECS0806M	Chairman & Managing Director	Remuneration		18	Approved	18	0	0								Textual Information(1)
2	Rajesh Lalit Mehta	AABPM9692H	Samrat Pharmachem Limited	AAECS0806M	Wholetime Director	Remuneration		15	Approved	15	0	0								Textual Information(2)
3	Megh Rajesh Mehta	BWDPM0880Q	Samrat Pharmachem Limited	AAECS0806M	Wholetime Director	Remuneration		7.5	Approved	7.5	0	0								Textual Information(3)
Total value of transaction during the reporting period											40.5									